Webs of (p,q) 5-branes, Five Dimensional Field Theories and Grid Diagrams

We continue to study 5d N=1 supersymmetric field theories and their compactifications on a circle through brane configurations. We develop a model, which we call (p,q) Webs, which enables simple geometrical computations to reproduce the known results, and facilitates further study. The physical concepts of field theory are transparent in this picture, offering an interpretation for global symmetries, local symmetries, the effective (running) coupling, the Coulomb and Higgs branches, the monopole tensions, and the mass of BPS particles. A rule for the dimension of the Coulomb branch is found by introducing Grid Diagrams. Some known classifications of field theories are reproduced. In addition to the study of the vacuum manifold we develop methods to determine the BPS spectrum. Some states, such as quarks, correspond to instantons inside the 5-brane which we call strips. In general, these may not be identified with (p,q) strings. We describe how a strip can bend out of a 5-brane, becoming a string. A general BPS state corresponds to a Web of strings and strips. For special values of the string coupling a few strips can combine and leave the 5-brane as a string.Comment: 72 pages, latex, 25 figures, references and small corrections adde

Switching to Aripiprazole as a Strategy for Weight Reduction: A Meta-Analysis in Patients Suffering from Schizophrenia

Weight gain is one of the major drawbacks associated with the pharmacological treatment of schizophrenia. Existing strategies for the prevention and treatment of obesity amongst these patients are disappointing. Switching the current antipsychotic to another that may favorably affect weight is not yet fully established in the psychiatric literature. This meta-analysis focused on switching to aripiprazole as it has a pharmacological and clinical profile that may result in an improved weight control. Nine publications from seven countries worldwide were analyzed. These encompassed 784 schizophrenia and schizoaffective patients, 473 (60%) men and 311 (40%) women, mean age 39.4 ± 7.0 years. The major significant finding was a mean weight reduction by −2.55 ± 1.5 kgs following the switch to aripiprazole (P < .001). Switching to an antipsychotic with a lower propensity to induce weight gain needs be explored as a strategy. Our analysis suggests aripiprazole as a candidate for such a treatment strategy

Clinical and psychosocial remission in schizophrenia: correlations with antipsychotic treatment

BACKGROUND: Clinical and psychosocial remission amongst persons with schizophrenia is nowadays a defined goal of treatment. This necessitates incorporating quantifiable psychosocial variables with traditional symptomatic data. We aimed to assess clinical and psychosocial remission in schizophrenia in a large cohort of community dwelling persons with schizophrenia. We emphasized between-groups comparison of antipsychotic medications and administration methods on the outcome of remission. METHODS: Psychiatric case managers rated psychosocial remission using the PsychoSocial Remission Scale (PSRS) and clinical remission using the Remission in Schizophrenia Working Group symptomatic remission criteria (RSWG). Ratings were performed for persons with schizophrenia they have been treating for 6 months or more. Data as to gender, age and pharmacological treatment of each patient were also collected. RESULTS: Of 445 participants who completed the survey, 268 (60%) were evaluated by psychiatrists, 161 (36%) by nurses and 16 (4%) were evaluated by social workers. Patients mean age was 43.4 + 13.1 years; 61% were men and 39% were women. Antipsychotic treatments were as follows: Per-os (PO) 243 (55%), IM long-acting typical antipsychotics (LAT) 102 (23%) and IM long-acting risperidone (RLAI; Consta) 100 (22%). Overall, 37% of patients achieved symptomatic remission and 31% achieved psychosocial remission. Rates of symptomatic remission were significantly higher in patients treated by LAT and RLAI compared with PO (51% and 48% vs., 29% respectively, p = 0.0003). Rates of psychosocial remission were also significantly higher in patients treated by LAT and RLAI compared with PO (43%% and 41% vs., 24% respectively, p = 0.003). CONCLUSION: In a large national sample a third of persons with schizophrenia were in remission. IM long acting preparations were associated with higher remission rates. Treatment choice may thus influence rates of remission in persons with schizophrenia